Sleep and Psychotropic Drugs

The Oxford Handbook of Sleep and Sleep Disorders

Volumn , Issue , 2012, Pages

  Riemann, Dieter ^a   Nissen, Christoph ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antidepressants; Benzodiazepines; GABA receptor agonists; Insomnia; Medication; Sleep; Stimulants

Indexed keywords

EID: 84923631777     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/oxfordhb/9780195376203.013.0011     Document Type: Chapter

References (150)

1. Agargun, M. Y., & Ozbek, H. (2006). Drug effects on dreaming. In M. Lader, D. P. Cardinali, & S. R. Pandi-Perumal (Eds.), Sleep and sleep disorders: A neuropsychopharmacological approach (pp. 256-261). Landes Bioscience/Eurekah.com and Springer Science + Business Media.
2. Aguayo, L. G., Peoples, R. W., Yeh, H. H., & Yevenes, G. E. (2002). GABA(A) receptors as molecular sites of ethanol action. Direct or indirect actions? Current Topics in Medical Chemistry, 2, 869-885.
3. Ancoli-Israel, S., Richardson, G. S., Mangano, R. M., Jenkins, L., Hall, P., & Jones, W. S. (2005). Long-term use of sedative hypnotics in older patients with insomnia. Sleep Medicine, 6, 107-113.
4. Backhaus, J., Junghanns, K., Mueller-Popkes, K., Brooks, A., Riemann, D., Hajak, G., & Hohagen, F. (2002). Short-term training increases diagnostic and treatment rate for insomnia in general practice. European Archives of Psychiatry and Clinical Neuroscience, 252, 99-104.
5. Ballard, C., & Howard, R. (2006). Neuroleptic drugs in dementia: Benefits and harm. Nature Reviews Neuroscience, 7, 492-500.
6. Basheer, R., Strecker, R. E., Thakkar, M. H., & McCarley, R. W. (2004). Adenosine and sleep-wake regulation. Progress in Neurobiology, 73, 379-396.
7. Beaulieu, P., & Walczak, J. S. (2007). Drugs for sleep pain/interactions: In G. Lavigne, B. J. Sessle, M. Choiniere, & P. J. Soja (Eds.), Sleep and pain (pp. 391-415). Seattle: IASP Press.
8. Benkert, O., & Hippius, H. (2007). Kompendium der Psychiatrischen Pharmakotherapie. Springer.
9. Bent, S., Padula, A., Moore, D., Patterson, M., & Mehling, W. (2006). Valerian for sleep: A systematic review and meta-analysis. American Journal of Medicine, 119, 1005-1012.
10. Bertrand, D. (2005). The possible contribution of neuronal nicotinic acetylcholine receptors in depression. Dialogues in Clinical Neuroscience, 7, 207-216.
11. Bradbury, M. J., Dement, W. C., & Edgar, D. M. (1998). Effects of adrenalectomy and subsequent corticosterone replacement on rat sleep state and EEG power spectra. American Journal of Physiology, 275(2 Pt 2), R555-65.
12. Brower, K. J., & Hall, J. M. (2001). Effects of age and alcoholism on sleep: A controlled study. Journal on Studies of Alcohol and Drugs, 62, 335-343.
13. Buckley, T. M., & Schatzberg, A. F. (2005). On the interactions of the hypothalamic-pituitary-adrenal (HPA) axis and sleep: Normal HPA axis activity and circadian rhythm, exemplary sleep disorders. Journal of Clinical Endocrinology and Metabolism, 90(5), 3106-3114.
14. Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L.,... Vohra, S. (2005). The efficacy and safety of exogenous melatonin for primary sleep disorders. Journal of General Internal Medicine, 20, 1151-1158.
15. Buscemi, N., Vandermeer, B., Hooton, N., Pandya, R., Tjosvold, L., Hartling, L.,... Baker, G. (2006). Efficacy and safety of exogenous melatonin for secondary sleep disorders accompanying sleep restriction: Meta-analysis. British Medical Journal, 332 (published online 10 February), 1-9.
16. Buysse, D. J. (1991). Drugs affecting sleep, sleepiness and performance. In T. H. Monk (Ed.), Sleep, sleepiness and performance (pp. 249-306). Chichester, United Kingdom: John Wiley & Sons.
17. Buysse, D. J., Schweitzer, P. K., & Moul, D. E. (2005). Clinical pharmacology of other drugs used as hypnotics. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice of sleep medicine (4th ed., pp. 452-467). Philadelphia, PA: Saunders.
18. Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Lichastein, K. L., & Morin, C. M. (2006). Recommendations for a standard research assessment of insomnia. Sleep, 29, 1155-1173.
19. Cagetti, E., Liang, J., Spigelman, I., & Olsen, R. W. (2003). Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABA (A) receptors. Molecular Pharmacology, 63, 53-64.
20. Cairns, B. E. (2007) Pain medication and sleep quality. In G. Lavigne, B. J. Sessle, M. Choiniere, & P.J. Soja (Eds.), Sleep and pain (pp. 371-390). Seattle: IASP Press.
21. Chernik, D. A., & Mendels, J. (1974). Longitudinal study of the effects of lithium carbonate on the sleep of hospitalized depressed patients. Biological Psychiatry, 9, 117-122.
22. Cohrs, S. (2008). Sleep disturbances in patients with schizophrenia. CNS Drugs, 22, 939-962.
23. Croog, S. H., Levine, S., Testa, M. A., Brown, B., Bulpitt, C. J., Jenkins, C. D.,... Williams, G. H. (1986). The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine, 314(26), 1657-1664.
24. Da Silva, A. M., Mendez, M., Bai, C., & Pandi-Perumal, S. R. (2006). Sleep and epilepsy: From interrelationships to influence of antiepileptic drugs. In M. Lader, D. P. Cardinali, & S. R. Pandi-Perumal (Eds.), Sleep and sleep disorders (pp. 282-296). New York:Springer.
25. Davis, K. L., Charney, D., Coyle, J. T., & Nemeroff, C. (2002). Neuropsychopharmacology. Philadelphia: Lippincott, Williams & Wilkins.
26. De Haas, S., Otte, A., de Weerd, A., van Erp, G., Cohen, A., & van Gerven, J. (2007). Exploratory polysomnographic evaluation of pregabalin on sleep disturbance in patients with epilepsy. Journal of Clinical Sleep Medicine, 3, 473-478.
27. DeMartinis, N. A., & Winokur, A. (2007). Effects of psychiatric medications on sleep and sleep disorders. CNS & Neurological Disorders-Drug Targets, 6, 17-29.
28. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. (2004). The health consequences of smoking: A report of the Surgeon General. Washington, DC: Author.
29. Dijk, D.-J., Brunner, D. P., Aeschbach, D., Tobler, I., Borbely, A. (1992). The effects of ethanol on human sleep EEG power spectra differ from those of benzodiazepine receptor agonists. Neuropsychopharmacology, 7, 225-232.
30. Doll, R., Peto, R., Boreham, J., & Sutherland, I. (2004). Mortality in relation to smoking: 50 years' observation on male British doctors. British Medical Journal, 328, 1519.
31. Dooley, D. J., Taylor, C. P., Donevan, S., & Feltner, D. (2007). Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends in Pharmacological Science, 28(2), 75-82.
32. Dubocovich, M. L., Masana, M. I., & Bernloucif, S. (1999). Molecular pharmacology and function of melatonin receptor subtypes. In J. Olcese (Ed.), Melatonin after four decades: An assessment of its potential (pp. 181-190). New York: Kluwer Academic/Plenum.
33. Dundar, Y., Boland, J., Strobl, J., Dodd, S., Haycox, A., Bagust, A.,... Walley, T. (2004a). Newer hypnotic drugs for the short-term management of insomnia: A systematic review and economic evaluation. Health Technology Assessment, 8, 24.
34. Dundar, Y., Dodd, S., Strobl, J., Boland, A., Dickson, R., & Walley, T. (2004b). Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: A systematic review and meta-analysis. Human Psychopharmacology, 19, 305-322.
35. Dunn, J. T., & Dunn, A. D. (2001). Update on intrathyroidal iodine metabolism. Thyroid, 11(5), 407-14. EMEA: http://www.emea.europa.eu/humandocs/PDFs/EPAR/circadin/H-695-de1.pdf, 2007.
36. Ermann, M., Seiden, D., Zammit, G., Sainati, S., & Zhang, J. (2006). An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Medicine, 7, 17-24.
37. Everson, C. A., & Nowak, T. S., Jr. (2002). Hypothalamic thyrotropin-releasing hormone mRNA responses to hypothyroxinemia induced by sleep deprivation. American Journal of Physiology- Endocrinology and Metabolism, 283(1), E85-93.
38. Feige, B., Voderholzer, U., Riemann, D., Hohagen, F., & Berger, M. (1999). Independent sleep EEG slow-wave and spindle band dynamics associated with 4 weeks of continuous application of short-half-life hypnotics in healthy subjects. Clinical Neurophysiology, 110, 1965-1974.
39. Feige, B., Gann, H., Brueck, R., Hornyak, M., Litsch, S., Hohagen, F., & Riemann, D. (2006). Effects of alcohol on polysomnographically recorded sleep in healthy subjects. Alcoholism: Clinical and Experimental Research, 30, 1527-1537.
40. Fischer, J., Mayer, G., Peter, H. J., Riemann, D., & Sitter, H. (2001). Nicht-erholsamer Schlaf [Non-restorative sleep]. Somnologie, 5, 1-258.
41. Franco, K. N., & Messinger-Rapport, B. (2006). Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. Journal of the American Medical Directors Association, 7, 201-202.
42. Friess, E., Tagaya, H., Grethe, C., Trachsel, L., & Holsboer, F. (2004). Acute cortisol administration promotes sleep intensity in man. Neuropsychopharmacology, 29(3), 598-604.
43. Friston, K. J., Sharpley, A. L., Solomon, R. A., & Cowen, P. J. (1989). Lithium increases slow wave sleep: Possible mediation by brain 5-HT receptors? Psychopharmacology, 98, 139-140.
44. Gann, H., van Calker, D., Feige, B., & Riemann, D. (2004). Die Bedeutung des Schlafs für gesunde Alkoholkonsumenten und alkoholabhängige Patienten. Nervenarzt, 75, 431-441.
45. Gary, K. A., Winokur, A., Douglas, S. D., Kapoor, S., Zaugg, L., & Dinges, D. F. (1996). Total sleep deprivation and the thyroid axis:Effects of sleep and waking activity. Aviation, Space and Environmental Medicine, 67(6), 513-9.
46. Gillin, J. C., & Drummond, S. P. (2000). Medication and substance abuse. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice of sleep medicine (3rd ed., pp. 1176-1195). Philadelphia, PA: Saunders.
47. Glass, J., Lanctot, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005). Sedative hypnotics in older people with insomnia: Metaanalysis of risks and benefits. British Medical Journal, 331, 1169-1175.
48. Gouzoulis, E., Steiger, A., Ennslin, M., Kovar, A., Hermle, L., (1992). Sleep EEG effects of 3,4-methylenedioxymethamphetamine (MDE, eve) in healthy volunteers. Biological Psychiatry, 32, 1108-1117.
49. Gresham, S. C., Webb, W. B., & Williams, R. L. (1963). Alcohol and caffeine: Effect on inferred visual dreaming. Science, 140, 1226-1227.
50. Guilleminault, C., & Frommherz, S. (2005). Narcolepsy: Diagnosis and management. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice of sleep medicine (4th ed., pp. 780-790). Philadelphia, PA: Saunders.
51. Gyllenhaal, C., Merritt, S. L., Peterson, S. D., Block, K. I., & Gochenor, T. (2000). Efficacy and safety of herbal stimulants and sedatives in sleep disorders. Sleep Medicine Reviews, 4, 229-251.
52. Hajak, G., & Rüther, E. (1995). Insomnie - Schlaflosigkeit - Ursachen, Symptomatik und Therapie. Berlin, Heidelberg, New York:Springer.
53. Hajak, G. (2006). Therapeutics of insomnia. New paradigms in pharmacological treatment of insomnia. Sleep Medicine, 7, S20-S26.
54. Hajak, G., Müller, W. E., Wittchen, H. U., Pittrow, D., & Kirch, W. (2003). Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone-a review of case reports and epidemiological data. Addiction, 98, 1371-1378.
55. Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F.,...Rüther, E. (2001). Doxepin in the treatment of primary insomnia. Journal of Clinical Psychiatry, 62, 453-463.
56. Hartmann, E., & Greenwald, D. (1984). Tryptophan and human sleep: An analysis of 43 studies. In H. G. Schlossberger, W. Kochen, B. Linzen, & H. Steinhart (Eds.), Progress in tryptophan and serotonin research (pp. 297-304). Berlin - New York: De Gruyter.
57. Hauger, R. L., & Datzenberg, F. M. (2000). Regulation of the stress response by corticotropin-releasing factor receptors. In P. M. Conn & M. E. Freeman (Eds.), Neuroendocrinology in physiology and medicine (pp. 261-287). Totowa: Humana Press.
58. Haupt, M., Cruz-Jentoft, A., & Jeste, D. (2006). Mortality in elderly dementia patients treated with risperidone. Journal of Clinical Psychopharmacology, 26, 566-70.
59. Hippius, H., Engel, R. R., & Laakmann, G. (1986). Benzodiazepine - Rückblick und Ausblick. Berlin - Heidelberg - New York - Tokyo:Springer-Verlag.
60. Herxheimer, A., & Petrie, K. J. (2002). Melatonin for the prevention and treatment of jet lag. Oxford: The Cochrane Library, Issue 4.
61. Hoffmann, F., Scharfetter, W., & Glaeske, G. (2009). Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007. Nervenarzt, 80, 578-583.
62. Hohagen, F., Rink, K., Käppler, C., Schramm, E., Riemann, D., Weyerer, S., & Berger, M. (1993). Prevalence and treatment of insomnia in general practice. European Archives of Psychiatry and Clinical Neuroscience, 242, 329-336.
63. Holbrook, A. M., Crowther, R., Lotter, A., Cheng, C., & King, D. (2000). Meta-analysis of benzodiazepine use in the treatment of insomnia. Canadian Medical Association Journal, 162, 225-233.
64. Horne, J. A., Percival, J. E., & Traynor, J. R. (1980). Aspirin and human sleep. Electroencephalography and Clinical Neurophysiology, 49, 409-413.
65. Hughes, J. R. (2007). Effects of abstinence from tobacco: Valid symptoms and time course. Nicotine & Tobacco Research, 9, 315-27.
66. Institute of Medicine (1979). Sleeping pills, insomnia and medical practice: Report of a study. Washington: National Academy of Sciences, Inst Med Publ, 10, 79-104.
67. Jaehne, A., Loessl, B., Barkai, Z., Riemann, D., & Hornyak, M. (2009). Effects of nicotine on sleep during consumption, withdrawal and replacement therapy. Sleep Medicine Reviews, 13(5), 363-77.
68. Jeste, D. V., Blazer, D., Casey, D., Meeks, T., Salzman, C., Schneider, L.,... Yaffe, K. (2007). ACNP white paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33, 957-970.
69. Jones, B. E. (2003). Arousal systems. Frontiers in Bioscience, 8, 438-451.
70. Jouvet, M. (1984). Indoleamines and sleep-inducing factors. Experimental Brain Research, 8, 84-94.
71. Julien, R. M. (1995). A primer of drug action: A concise, nontechnical guide to the actions. New York: Freeman & Company.
72. Kanno, O., & Clarenbach, P. (1985). Effect of clonidine and yohimbine on sleep in man: Polygraphic study and EEG analysis by normalized slope descriptors. Electroencephalography and Clinical Neurophysiology, 60(6), 478-484.
73. Katzung, B., Masters, S., & McGraw-Hill, A. (2009). Basic and clinical pharmacology (11th ed.). New York: The McGraw-Hill Companies, Inc.
74. Korf, H. W., Schomerus, C., & Stehle, J. H. (1998). The pineal organ, its heroine melatonin, and the photoneuroendocrine system. New York: Springer.
75. Kripke, D. F., Garfinkel, I., & Wingard, D. L. (2002). Mortality associated with sleep duration and insomnia. Archives of General Psychiatry, 59, 131-136.
76. Kripke, D. F. (2006). Risks of chronic hypnotic use. In M. Lader, D. P. Cardinali, & S. R. Pandi-Perumal (Eds.), Sleep and sleep disorders-a neuropsychopharmacological approach (pp. 141-145). New York: Springer.
77. Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amto, D. A., Wessel, T. C., & Roth, T. (2003). Sustained efficacy of eszopiclone over 6 months of nightly treatment: Results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep, 26, 793-799.
78. Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., Roth, T., ZOLONG study group. (2008). Long-term efficacy and safety of zolpidem extended-release 12,5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: A 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study. Sleep, 31, 79-90.
79. Kumari, M., & Ticku, M. K. (2000). Regulation of NMDA receptors by ethanol. Progress in Drug Research, 54, 152-189.
80. Kupfer, D. J., Wyatt, R. J., Greenspan, K., & Snyder, F. (1970). Lithium carbonate and sleep in affective illness. Archives of General Psychiatry, 23, 35-40.
81. Kupfer, D. J., Reynolds, C. F., Weiss, B. L., & Foster, F. G. (1974). Lithium carbonate and sleep in affective disorders. Archives of General Psychiatry, 30, 79-84.
82. Landolt, H. P., Roth, C., Dijk, D.-J., Borbely A. (1996). Late-afternoon ethanol intake affects nocturnal sleep and the sleep EEG in middle-aged man. Journal of Clinical Psychopharmacology, 16, 428-436.
83. Lange, K., Wodarz, N., & Hajak, G. (2007). Abhängigkeitspotential der GABAa-Rezeptor-agonistischen Nichtbenzodiazepin-Hypnotika. Sucht, 53, 201-213.
84. Léger, D., Guilleminault, C., Bader, G., Levy, E., & Paillard, M. (2002). Medical and socio-professional impact of insomnia. Sleep, 25, 625-629.
85. Léger, D. (2007). Insomnia: Impact on work, economics, and quality of life. In D. Léger & S. R. Pandi-Perumal (Eds.), Sleep disorders-their impact on public health (pp. 137-154). London: Informa Healthcare.
86. Lydic, R., & Baghdoyan, H. (2007). Neuronal mechanisms mediating opioid-induced REM sleep disruption. In G. Lavigne, B. J. Sessle, M. Choinière, & P. J. Soja (Eds.), Sleep and pain (pp. 99-122). Seattle: IASP Press.
87. Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004). The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Science USA, 101(26), 9861-9866.
88. Martin, S. A., Aikens, J. E., & Chervin, R. D., (2004). Toward cost-effectiveness analysis in the diagnosis and treatment of insomnia. Sleep Medicine Reviews, 8, 63-72.
89. MacLean, A. W., & Cairns, J. (1982). Dose-response effects of ethanol on the sleep of young men. Journal of Studies on Alcohol and Drugs, 43, 434-444.
90. Madsen, B. W., & Rossi, L. (1980). Sleep and Michaelis-Menten elimination of ethanol. Clinical Pharmacology & Therapeutics, 27, 114-119.
91. Maxion, H. (1968). Erfahrungen mit Tegretal im polygraphischen Schlaf-EEG. Nervenarzt, 12, 547-549.
92. McAinsh, J., & Cruickshank, J.M. (1990). Beta-blockers and central nervous system side effects. Pharmacol Ther. 46(2): 163-97.
93. McGechan, A., & Wellington, K. (2005). Ramelteon. CNS Drugs, 19, 1057-1065.
94. Mendelson, W. B., Roth, T., Cassella, J., Roehrs, T., Walsh, J. K., Woods, J. H.,... Meyer, R. E. (2004). The treatment of chronic insomnia: Drug indications, chronic use and abuse liability. Summary of a 2001 new clinical drug evaluation unit meeting symposium. Sleep Medicine Reviews, 8, 7-17.
95. Mendelson, W. B. (2005). Hypnotic medications: Mechanisms of action and pharmacological effects. In M. H. Kryger, T. Roth, & W. C. Dement (Eds.), Principles and practice of sleep medicine (4th ed., pp. 444-451). Philadelphia, PA: Saunders.
96. Mendelson, W. B. (2005). A review of the evidence for the efficacy and safety of trazodone in insomnia. Journal of Clinical Psychiatry, 66, 469-476.
97. Montgomery, S. A., Herman, B. K., Schweizer, E., & Mandel, F. S. (2009). The efficacy of pregabaline and benzodiazepines in generalized anxiety disorder presenting with high levels of insomnia. International Clinical Psychopharmacology, 24, 214-222.
98. Monti, J. M. (1987). Disturbances of sleep and wakefulness associated with the use of antihypertensive agents. Life Sci. 41(17), 1979-1988.
99. Monti, J. M., & Monti, D. (2004). Sleep in schizophrenia patients and the effects of antipsychotic drugs. Sleep Medicine Reviews, 8, 133-148.
100. Morin, C. M., Vallieres, A., Guay, B., Ivers, H., Savard, J., Merette, C.,... Baillargeon, L. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia. Journal of the American Medical Association, 301, 2005-2015.
101. National Institutes of Health State of the Science Conference Statement. (2005). Manifestations and management of chronic insomnia in adults. Sleep, 28, 1049-1057.
102. National Institute on Drug Abuse. (2006a). Monitoring the future. National results on adolescent drug use. Overview of key findings 2006. Retrieved from http://www.monitoringthefuture.org/.
103. National Survey on Drug Use and Health. (2006b). Results from the 2006 National Survey on Drug Use and Health: National findings. Retrieved from http://nsduhweb.rti.org/.
104. Nicholson, A. N. (1983). Antihistamines and sedation. Lancet, 322(8343), 211-212.
105. Nowell, P. D., Mazumdar, S., Buysse, D. J., Dew, M. A., Reynolds, C. F., & Kupfer, D. J. (1997). Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. Journal of the American Medical Association, 278, 2170-2177.
106. No author listed (2003). Melatonin-controlled release-neurim pharmaceuticals. Circadin, melatonin-prolonged release, melatoninsustained release. Drugs RD, 4(2), 131-132.
107. Oswald, I. (1984). Hypnotic drugs for 1984. In I. Hindmarch, H. Ott, & T. Roth (Eds.), Sleep, benzodiazepines and performance (pp. 84-90). Berlin - Heidelberg - New York - Tokyo: Springer-Verlag.
108. Papineau, K., Roehrs, T., Petrucelli, N., Rosenthal, L., & Roth, T. (1988). Electrophysiological assessment (Multiple Sleep Latency Test) of the biphasic effects of ethanol in humans. Alcoholism: Clinical and Experimental Research, 22, 231-235.
109. Perlis, M. L., McCall, W. V., Krystal, A. D., & Walsh, J. K. (2004). Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. Journal of Clinical Psychiatry, 65, 1128-1137.
110. Pohorecky, L. A. (1977). Biphasic action of ethanol. Biobehavioral Reviews, 1, 231-240.
111. Prince, J. B., Wilens, T. E., Biederman, J., Spencer, T. J., & Wozniak, J. R. (1996). Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: A systematic chart review of 62 cases. Journal of the American Academy of Child and Adolescent Psychiatry, 35(5), 599-605.
112. Rickels, K., Morris, R. J., Newman, H., Rosenfeld, H., Schiller, H., & Weinstock, R. (1983). Diphenhydramine in insomniac family practice patients: A double-blind study. Journal of Clinical Pharmacology, 23, 235-242.
113. Rickels, K., Ginsberg, J., & Morris, R. J. (1984). Doxylamine succinate in insomniac family practice patients: A double-blind study. Current Therapeutic Research, 35, 532-540.
114. Riemann, D., Gann, H., Hohagen, F., Bahro, M., Müller, W. E., & Berger, M. (1993). The effect of carbamazepine on endocrine and sleep EEG variables in a patient with 48-hour rapid cycling, and healthy controls. Neuropsychobiology, 27, 163-170.
115. Riemann, D., Berger, M., & Voderholzer, U. (2001). Sleep and depression-results from psychobiological studies: An overview. Biological Psychology, 57, 67-103.
116. Riemann, D., Voderholzer, U., Cohrs, S., Rodenbeck, A., Hajak, G., Rüther, E.,... Berger, M. (2002). Trimipramine in primary insomnia:Results of a polysomnographic double-blind controlled study. Pharmacopsychiatry, 35, 165-174.
117. Riemann, D., Klein, T., Rodenbeck, A., Feige, B., Horny, A., Hummel, R.,... Voderholzer, U. (2002). Nocturnal cortisol and melatonin secretion in primary insomnia. Psychiatry Research, 113(1-2), 17-27.
118. Riemann, D., & Voderholzer, U. (2003). Der gestörte Schlaf: Via regia zum Verständnis depressiver Erkrankungen. Bremen: Uni-Med.
119. Riemann, D., & Perlis, M. L. (2009). The treatments of chronic insomnia: A review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Medicine Reviews, 13, 205-214.
120. Riemann, D., Spiegelhalder, K., Feige, B., Voderholzer, U., Berger, M., Perlis, M., & Nissen, C. (2009). The hyperarousal model of insomnia: A review of the concept and its evidence. Sleep Medicine Reviews, 27. [Epub ahead of print] PubMed PMID: 19481481.
121. Roehrs, T., Yoon, J., & Roth, T. (1991). Nocturnal and next-day effects of ethanol and basal level of sleepiness. Human Psychopharmacology, 6, 307-311.
122. Roehrs, T., & Roth, T. (1998). State altering actions of ethanol, caffeine, and nicotine. In R. Lydic & H. A. Baghdoyan (Eds.), Handbook of behavioral state control: Cellular and molecular mechanisms (pp. 421-430). New York: CRC Press.
123. Roehrs, T., & Roth, T. (2008). Caffeine: Sleep and daytime sleepiness. Sleep Medicine Reviews, 12, 153-162.
124. Roehrs, T., Tietz, E., Zorick, F., & Roth, T. (1984). Daytime sleepiness and antihistamines. Sleep, 7, 137.
125. Roth, T., Seiden, D., Sainati. S., Wang-Weigand, S., Zhang, J., & Zee, P. (2006). Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Medicine, 7, 312-318.
126. Roth, T., Rogowski, R., Hull, S., Schwartz, H., Koshorek, G., Corser, B., & Seiden, D. (2007). Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep, 30, 1555-1561.
127. Rundell, O. H., Lester, B. K., Griffiths, W. J., Williams, H. L. (1972). Alcohol and sleep in young adults. Psychopharmacologia, 26, 201-218.
128. Sammaritano, M., & Sherwin, A. (2000). Effect of anticonvulsants on sleep. Neurology, 54, S16-S24.
129. Saper, C. B., Scammell, T. E., & Lu, J. (2005). Hypothalamic regulation of sleep and circadian rhythms. Nature, 437, 1257-1263.
130. Sateia, M. J., Kirby-Long, P., & Taylor, J. L. (2008). Efficacy and clinical safety of ramelteon: An evidence-based review. Sleep Medicine Reviews, 12, 319-332.
131. Schierenbeck, T., Riemann, D., Berger, M., & Hornyak, M. (2008). Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana. Sleep Medicine Reviews, 12, 381-390.
132. Shiyi, L., & Inoué, S. (1995). Sleep: Ancient and modern. Shanghai - Tokyo: The Shanghai Scientific and Technological Literature Publishing House, The Asian Sleep Research Society.
133. Steiger A. (1999). Thyroid gland and sleep. Acta Med Austriaca, 26(4), 132-133.
134. Stevinson, C., & Ernst, E. (2000). Valerian for insomnia: A systematic review of randomized clinical trials. Sleep Medicine, 1, 91-99.
135. Taibi, D. M., Landis, C. A., Petry, H., & Vitiello, M. V. (2007). A systematic review of valerian as a sleep aid: Safe but not effective. Sleep Medicine Reviews, 11, 209-232.
136. Thompson, D. F., & Pierce, D. R. (1999). Drug-induced nightmares. Annals of Pharmacotherapy, 33(1), 93-8.
137. Tsigos, C., & Chrousos, G. P. (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. Journal of Psychosomatic Research, 53(4), 865-871.
138. Van Cauter, E., & Turek, F. W. (1995). Endocrine and other biological rhythms. In L. J. DeGroot (Ed.), Endocrinology (3rd ed., pp. 2497-2548). Philadelphia: Saunders.
139. Vanderpump, M., & Tunbridge, M. (2008). Thyroid disease (4th ed.). Oxford: Oxford University Press.
140. Vgontzas, A. N., Tsigos, C., Bixler, E. O., Stratakis, C. A., Zachman, K., Kales, A.,... Chrousos, G. P. (1998). Chronic insomnia and activity of the stress system: A preliminary study. Journal of Psychosomatic Research, 45(1 Spec No), 21-31.
141. Voderholzer, U., Riemann, D., Hornyak, M., Backhaus, J., Feige, B., Berger, M., & Hohagen, F. (2001). A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects. European Archives of Psychiatry and Clinical Neurosciences, 251, 117-223.
142. Walsh, J. K., Erman, M., Erwin, M., Erwin, C. W., Jamieson, A., Mahowald, M.,... Ware, J.C. (1998). Subjective hypnotic efficacy of trazodone and zolpidem in DMS-III-R primary insomnia. Human Psychopharmacology, 13, 191-198.
143. Walsh, J. K., & Schweitzer, P. K. (1999). Ten-year trends in the pharmacological treatment of insomnia. Sleep, 22, 371-375.
144. Walsh, J. K., Roth, T., Randazzo, A., Erman, M., Jamieson, A., Scharf, M.,... Ware, J. C. (2000). Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep, 23, 1087-1096.
145. Walsh, J. K. (2004). Drugs used to treat insomnia in 2002: Regulatory-based rather than evidence-based medicine. Sleep, 27, 1441.
146. Walsh, J. K., Krystal, A. D., Amato, D. A., Rubens, R., Caron, J., Wessel, T. C.,... Roth, T. (2007). Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations. Sleep, 30, 959-968.
147. Williams, H., & Salamy, A. (1972). Alcohol and sleep. In B. Kissin & H. Begleiter (Eds.), The biology of alcoholism (pp. 435-483). New York: Plenum Press.
148. Yang, J. D., Elphick, M., Sharplex, A. L., & Cowen, P. J. (1989). Effects of carbamazepine on sleep in healthy volunteers. Biological Psychiatry, 26, 324-328.
149. Yules, R. B., Freedman, D. X., & Chandler, K. A. (1966). The effect of ethyl alcohol on man's electroencephalographic sleep cycle. Electroencephalography and Clinical Neurophysiology, 20, 109-111.
150. Zwingenberger, K., & Wnendt, S. (1995). Immunomodulation by thalidomide: Systematic review of the literature and of unpublished observations. Journal of Inflammation, 46, 177-211.